Drug Sales Trends for DEPO-PROVERA

Annual Sales Revenues and Units Sold for DEPO-PROVERA

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
DEPO-PROVERA			2021
DEPO-PROVERA			2020
DEPO-PROVERA			2019
DEPO-PROVERA			2018
DEPO-PROVERA			2017
DEPO-PROVERA			2016
DEPO-PROVERA			2015

Market Analysis and Sales Projections for Depo-Provera

Introduction to Depo-Provera

Depo-Provera, also known as medroxyprogesterone acetate (MPA), is a widely used injectable contraceptive. It is administered either intramuscularly or subcutaneously and is effective for up to three months, making it a popular choice for women seeking a reliable and low-maintenance contraceptive method.

Market Share and Dominance

As of 2021, Depo-Provera controlled approximately 60% of the global phase III progesterone-only injectable contraceptives market. This dominance is attributed to its high efficacy, with a failure rate of only about 4% per year, making it 96% effective in preventing pregnancy[1].

Market Drivers

Several factors are driving the growth of the injectable contraceptives market, including Depo-Provera:

• Increasing Awareness: There is a growing awareness about the benefits of injectable contraceptives, particularly among women who cannot use estrogen-based contraceptives. This increased knowledge is a significant driver for the market[1].
• Unmet Need: Despite the availability of modern contraceptive methods, 257 million women worldwide want to prevent pregnancies but are not using these methods. Fulfilling this unmet need is expected to expand the market for injectable contraceptives[1].
• Resumption of Healthcare Services: Post-pandemic, as clinics and hospitals resume their services, there is an anticipated increase in demand for contraceptive screening and procedures, which will drive the sales of Depo-Provera and other injectable contraceptives[3].

Market Segmentation

The injectable contraceptives market is segmented into several categories:

• Product Type: The market is divided into progesterone-only injectables (such as depot medroxyprogesterone acetate and norethisterone enanthate) and combined injectable contraceptives. Progesterone-only injectables, particularly Depo-Provera, are the fastest-growing segment due to their effectiveness and reliability[1].
• Administration Route: Depo-Provera can be administered either intramuscularly or subcutaneously. The intramuscular route is more common and accounts for a significant portion of the market[4].
• Age Group: The market is also segmented by age group, with the 15-24 and 25-34 age groups being significant consumers of injectable contraceptives[1].

Sales Projections

Global Market

The global injectable contraceptives market, led by Depo-Provera, is expected to see substantial growth. Here are some key projections:

• Revenue Growth: The U.S. injectable contraceptives market is projected to reach more than USD 339.6 million by 2031, growing at a CAGR of 3.0% from 2023 to 2031[4].
• Historical Data: In the United States, Depo-Provera had annual sales of approximately $211 million in 2017 and $181 million for the 12 months ending July 31, 2018[2][5].

U.S. Market

The U.S. market for long-acting contraceptives, including injectables like Depo-Provera, is also on the rise:

• Market Size: The U.S. long-acting contraception market was valued at USD 1.8 billion in 2021 and is forecasted to reach USD 2.5 billion by 2028, growing at a CAGR of 4.69% from 2021 to 2028[3].
• Impact of COVID-19: The pandemic led to a decline in sales for some contraceptive products, including a 14.1% decline in Implanon sales in 2020 compared to 2019. However, as healthcare services resume, the demand for Depo-Provera and other injectable contraceptives is expected to rebound[3].

Key Players

Several pharmaceutical companies play a crucial role in the market for Depo-Provera and other injectable contraceptives:

• Pfizer: The original manufacturer of Depo-Provera, although it has faced production challenges, including a temporary halt in manufacturing at its Kalamazoo production site until early 2022[3].
• Teva Pharmaceuticals: Teva reintroduced the generic equivalent of Depo-Provera in the United States, expanding the market options and accessibility of the drug[2].
• Mylan: Mylan launched a generic version of Depo-Provera, further increasing competition and availability in the market[5].

Challenges and Considerations

While Depo-Provera is highly effective, there are some challenges and considerations:

• Bone Mineral Density: Long-term use of Depo-Provera can lead to significant bone mineral density loss, which may not be completely reversible. This is particularly concerning for adolescents and young adults, who are in a critical period of bone accretion[5].
• COVID-19 Impact: The pandemic affected the production and distribution of various contraceptive products, including Depo-Provera. However, as healthcare services normalize, these impacts are expected to diminish[3].

Distribution Channels

The distribution of Depo-Provera and other injectable contraceptives is crucial for their accessibility:

• Hospital Pharmacies: These are among the primary distribution channels, accounting for a significant share of the market[4].
• Retail Pharmacies: Retail pharmacies also play a vital role in distributing these products, making them more accessible to a broader audience[4].
• Online Pharmacies: The rise of online pharmacies is another distribution channel that is expected to grow, especially as healthcare services become more digitalized[4].

Key Takeaways

• Market Dominance: Depo-Provera dominates the injectable contraceptives market with a 60% global market share.
• Growth Projections: The U.S. injectable contraceptives market is projected to grow at a CAGR of 3.0% from 2023 to 2031.
• Increasing Awareness: Growing awareness about the benefits of injectable contraceptives is a significant market driver.
• Challenges: Long-term use of Depo-Provera can lead to bone mineral density loss, and the COVID-19 pandemic has impacted production and distribution.

FAQs

1. What is Depo-Provera, and how is it administered? Depo-Provera, or medroxyprogesterone acetate (MPA), is an injectable contraceptive that can be administered either intramuscularly or subcutaneously. It is effective for up to three months.

2. What is the market share of Depo-Provera in the global injectable contraceptives market? As of 2021, Depo-Provera controlled about 60% of the global phase III progesterone-only injectable contraceptives market.

3. What are the key drivers of the injectable contraceptives market? Key drivers include increasing awareness about the benefits of injectable contraceptives, unmet need for modern contraceptive methods, and the resumption of healthcare services post-pandemic.

4. How has the COVID-19 pandemic affected the sales of Depo-Provera? The pandemic led to a decline in sales for some contraceptive products due to reduced demand and production challenges. However, as healthcare services resume, demand is expected to rebound.

5. What are the potential health considerations associated with long-term use of Depo-Provera? Long-term use of Depo-Provera can lead to significant bone mineral density loss, which may not be completely reversible, particularly concerning for adolescents and young adults.

Sources

1. Stellar Market Research: "Injectable Contraceptives Market - Industry Analysis and Forecast 2024-07-16"
2. Teva Pharmaceutical Industries Ltd.: "Teva Announces Reintroduction of Generic Depo-Provera® in the United States"
3. Grand View Research: "U.S. Long-acting Contraception Market Size Report, 2028"
4. Transparency Market Research: "U.S. Injectable Contraceptives Market Research Report, 2031"
5. PR Newswire: "Mylan Adds to Women's Healthcare Portfolio With Launch of Generic Depo-Provera Injection"